This study systematically characterizes the molecular landscape of resistance to KRASG12C inhibitors, providing critical experimental evidence for understanding resistance mechanisms and guiding subsequent therapeutic strategies in non-small cell lung cancer and colorectal cancer.
Literature Overview
The article titled 'Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors,' published in Annals of oncology: official journal of the European Society for Medical Oncology, systematically investigates acquired genomic alterations in cancer patients who have progressed after treatment with KRASG12C inhibitors. By integrating cfDNA sequencing data from 143 patients across multiple centers, the study comprehensively characterizes resistance-associated variants in the RAS/MAPK pathway and validates their functional significance using engineered cell models. Furthermore, it evaluates the inhibitory potential of novel KRAS inhibitors against these resistance mutations, offering new insights into overcoming therapeutic resistance.Background Knowledge
Currently, KRAS mutations are among the most common oncogenic drivers in solid tumors, particularly prevalent in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). For a long time, KRAS was considered an 'undruggable' target until the development of KRASG12C-specific covalent inhibitors such as sotorasib and adagrasib. Although these drugs have shown objective response rates of approximately 30–40% in NSCLC, their monotherapy efficacy is limited in CRC, and nearly all patients eventually progress due to acquired resistance. A major challenge in current research is the high heterogeneity of resistance mechanisms, including KRAS amplification, NRAS mutations, MAP2K1 mutations, BRAF fusions, among others, with significant differences observed across tumor types. Additionally, some resistance mechanisms involve non-genomic changes such as EMT or histological transformation, further complicating treatment strategies. This study addresses these challenges by systematically integrating multicenter clinical cohort data with functional validation and pharmacological evaluation of novel inhibitors, aiming to comprehensively dissect the genomic landscape of resistance to KRASG12C inhibitors and explore the clinical translational potential of next-generation KRAS-targeted therapies.
Research Methods and Experiments
The study employed a multicenter retrospective cohort design, enrolling 143 cancer patients who progressed after KRASG12C inhibitor therapy. High-throughput sequencing data from post-progression plasma cfDNA were analyzed to systematically identify acquired genomic alterations. The sequencing platforms used included GuardantOMNI, Guardant360 CDx, and FoundationOne Liquid CDx, ensuring comprehensive coverage of key genes in the RAS/MAPK pathway such as KRAS, NRAS, HRAS, BRAF, and MAP2K1. To validate the functional impact of candidate resistance variants, the study generated double-mutant MIA PaCa-2 cell lines (with endogenous KRASG12C background) harboring various resistance mutations, and assessed changes in IC50 values for inhibitors such as sotorasib, adagrasib, and divarasib using cell viability assays. Additionally, the activity of three novel KRAS inhibitors—RM-018 (a RAS(ON) G12C ternary complex inhibitor), Pan-KRAS-IN-1 (a KRAS-selective inhibitor), and RMC-7977 (a RAS(ON) pan-mutant ternary complex inhibitor)—was evaluated in these models to assess their potential to overcome resistance.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a clear resistance target landscape for drug development, supporting the design of precision KRAS inhibitor combinations or sequential strategies tailored to specific resistance mechanisms. For clinical monitoring, dynamic cfDNA analysis can detect resistant clones months before radiographic progression, enabling earlier intervention. Moreover, the study underscores the importance of disease modeling—developing cell and animal models harboring diverse resistance mutations will facilitate systematic evaluation of the broad-spectrum activity and resistance boundaries of novel KRAS inhibitors, ultimately accelerating the development of more effective therapies.
Conclusion
This study systematically reveals the genomic complexity of acquired resistance to KRASG12C inhibitors through large-scale clinical cohorts and functional validation, particularly highlighting the frequent polyclonal activation of the RAS/MAPK pathway in colorectal cancer. It not only identifies key resistance mechanisms such as KRAS amplification, activating mutations, and switch-II pocket mutations, but more importantly proposes viable strategies to overcome them—RAS(ON) ternary complex inhibitors and pan-KRAS inhibitors demonstrate broad-spectrum activity against resistance. From bench to bedside, these findings provide a molecular foundation for designing post-resistance treatment regimens, advancing the field from a 'single-inhibitor' approach toward a 'resistance-mechanism-guided' precision therapy paradigm. In the future, integrating dynamic cfDNA monitoring with resistance mechanism analysis may enable individualized sequential therapies, significantly extending survival for patients with KRAS-mutant tumors. This study lays a critical cornerstone for precision treatment in non-small cell lung cancer and colorectal cancer, marking a new era in KRAS-targeted therapy focused on overcoming resistance.
